AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Navigating FDA Approval and Off-Label Use of Ketamine for Mental Health
This chapter explores the FDA's cautious approach to ketamine for mental health, focusing on obstacles related to its off-patent status and the implications for clinical trials. It contrasts the unregulated off-label use with the stricter approval process for S-ketamine, emphasizing patient experiences alongside regulatory hurdles.